These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32278710)

  • 1. Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2.
    Kuriwaki I; Kameda M; Hisamichi H; Kikuchi S; Iikubo K; Kawamoto Y; Moritomo H; Kondoh Y; Amano Y; Tateishi Y; Echizen Y; Iwai Y; Noda A; Tomiyama H; Suzuki T; Hirano M
    Bioorg Med Chem; 2020 May; 28(10):115453. PubMed ID: 32278710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of octahydropyrrolo [3,2-b] pyridin derivative as a highly selective Type I inhibitor of FGFR3 over VEGFR2 by high-throughput virtual screening.
    Wang X; Ye CH; Li EM; Xu LY; Lin WQ; Chen GH
    J Cell Biochem; 2023 Feb; 124(2):221-238. PubMed ID: 36502529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.
    Kuriwaki I; Kameda M; Iikubo K; Hisamichi H; Kawamoto Y; Kikuchi S; Moritomo H; Kondoh Y; Terasaka T; Amano Y; Tateishi Y; Echizen Y; Iwai Y; Noda A; Tomiyama H; Nakazawa T; Hirano M
    Bioorg Med Chem; 2021 Mar; 33():116019. PubMed ID: 33486159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.
    Kankanala J; Latham AM; Johnson AP; Homer-Vanniasinkam S; Fishwick CW; Ponnambalam S
    Br J Pharmacol; 2012 May; 166(2):737-48. PubMed ID: 22141913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
    Sun W; Hu S; Fang S; Yan H
    Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.
    Hirose M; Okaniwa M; Miyazaki T; Imada T; Ohashi T; Tanaka Y; Arita T; Yabuki M; Kawamoto T; Tsutsumi S; Sumita A; Takagi T; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
    Bioorg Med Chem; 2012 Sep; 20(18):5600-15. PubMed ID: 22883026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
    Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
    Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
    Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W
    J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation.
    Oguro Y; Miyamoto N; Okada K; Takagi T; Iwata H; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
    Bioorg Med Chem; 2010 Oct; 18(20):7260-73. PubMed ID: 20833055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of substituted 1,2,3-benzotriazines and pyrido[3,2-d]-1,2,3-triazines as inhibitors of vascular endothelial growth factor receptor-2.
    Zhao XW; Liu D; Luan SL; Hu GD; Lv JL; Jing YK; Zhao LX
    Bioorg Med Chem; 2013 Dec; 21(24):7807-15. PubMed ID: 24189187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
    Salerno S; García-Argáez AN; Barresi E; Taliani S; Simorini F; La Motta C; Amendola G; Tomassi S; Cosconati S; Novellino E; Da Settimo F; Marini AM; Via LD
    Eur J Med Chem; 2018 Apr; 150():446-456. PubMed ID: 29547832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel substituted benzo-anellated 4-benzylamino pyrrolopyrimidines as dual EGFR and VEGFR2 inhibitors.
    Fischer T; Krüger T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2708-2712. PubMed ID: 28478927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
    Shi W; Qiang H; Huang D; Bi X; Huang W; Qian H
    Eur J Med Chem; 2018 Oct; 158():814-831. PubMed ID: 30248654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.
    Miyazaki Y; Maeda Y; Sato H; Nakano M; Mellor GW
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1967-71. PubMed ID: 18280153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
    Adel M; Serya RAT; Lasheen DS; Abouzid KAM
    Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and preclinical evaluation of 5-methyl-N
    Devambatla RKV; Choudhary S; Ihnat M; Hamel E; Mooberry SL; Gangjee A
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3085-3093. PubMed ID: 30098869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
    Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
    Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
    Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
    Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.